From the Department of Chemistry, Princeton
University, Princeton, New Jersey 08544, the § Howard Hughes
Medical Institute and Department of Biochemistry, University of Texas
Southwestern Medical Center, Dallas, Texas 75235, and the
Department of Chemistry, Drexel University, Philadelphia,
Pennsylvania 19104
Received for publication, October 26, 2000, and in revised form, December 6, 2000
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cytochrome c (Cc) binding to
apoptosis protease activation factor-1 (Apaf-1) is a critical
activation step in the execution phase of apoptosis. Here we report
studies that help define the Cc:Apaf-1 binding surface. It is
shown that a large number of Cc residues, including residues 7, 25, 39, 62-65, and 72, are involved in the Cc:Apaf-1 interaction. Mutation of
residue 72 eliminated Cc activity whereas mutations of residues 7, 25, 39, and 62-65 showed reduced activity in an additive fashion. The implications of this binding model for both recognition and modulation of protein-protein interactions are briefly discussed.
The importance of apoptosis, or "programmed cell death," for
multicellular organisms is well established. One key apoptotic pathway
in vertebrates is triggered when the mitochondrial protein cytochrome
c (Cc)1 is
released from mitochondria (1). In the cytosol, Cc binds strongly to
apoptosis protease activation factor-1 (Apaf-1) (2). In the presence of
dATP and perhaps other cofactors, the Cc:Apaf-1 complex assembles into
a multimeric "apoptosome" that binds and activates a protease
zymogen, procaspase-9 (3-6). The activated caspase-9 cleaves and
activates procaspase-3 and other downstream caspases in a "caspase
cascade". The active caspases in turn cleave many intracellular
substrates, thereby disabling important cellular processes and breaking
down structural components of the cell (see Refs. 7 and 8 and for
reviews see Refs. 9-12). The initial Cc:Apaf-1 binding is a critical
step in this process and therefore represents a potential therapeutic
target. To date, our understanding of this interaction is very limited.
Here we report studies that help identify the molecular determinants of this interaction.
Horse Cc can initiate caspase activation in an in vitro
reconstitution system containing Cc, Apaf-1, dATP, procaspase-9, and procaspase-3. However, the highly homologous yeast Cc cannot substitute horse Cc to initiate activation (13) and, in fact, does not measurably
bind to Apaf-1 (as described under "Results and Discussion"). This
result is surprising, because the sequences of yeast Cc and horse Cc
are highly homologous. These sequences are most strongly conserved at
the "front face lysine patch," which is involved in all previously
studied physiological complexes of Cc (14) (Fig.
1, A and B). For
example, yeast cytochrome c peroxidase can bind
almost equally well with yeast and horse Cc (15).
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
View larger version (51K):
[in a new window]
Fig. 1.
A, sequence alignment for human,
horse, Drosophila, and yeast cytochromes c (26).
The horse cytochrome c numbering system is used. A single
letter code X is used to represent the -N-trimethyl
lysine residue. Identical amino acid residues are labeled by
boxes with gray shading. B, the
helix-and-strand structures of yeast Cc (1YCC) and horse Cc
(1HRC) are overlaid in three dimensions. This figure was generated by
Raster3D (27) and MOLSCRIPT (28). The yeast Cc is red with
heme in cyan, whereas horse Cc is purple with
heme in blue.
Our current studies focus on key differences between the horse and
yeast Cc, including residues 1-9, 53-60, 62-65, 25, and 39, as well
as position 72, which is trimethylated in fungi but not in higher
eukaryotes (the horse cytochrome c numbering system is used
in this article). Two complementary classes of mutagenesis experiments
were carried out, and the mutant Cc were used to activate procaspase-9
in the reconstituted Apaf-1-mediated caspase activation reaction. In
the first set of experiments, horse Cc residues were mutated to the
yeast sequence, whereas in the complementary experiments, yeast Cc
residues were replaced by the horse Cc sequence.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Fluorescence Polarization Methods-- Steady-state fluorescence experiments were performed using a Photon Technologies International (South Brunswick, NJ) Quantamaster fluorometer equipped with a PowerArc xenon arc lamp excitation source. The instrument was fitted with Glan-Thompson manual polarizers. Data were recorded using FeliX software for Windows, Version 3.1. Polarization experiments were performed in a 10-mm pathlength quartz cuvette containing 2 ml of Buffer A (20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM Na4EDTA, pH 7.5) as described previously (16). Apaf-1 (in the presence or absence of excess Fe yeast Cc) in Buffer A (2-4 µM) was titrated into a 100 nM solution of yeast porphyrin Cc, fluorescent derivative of yeast Cc where the free base porphyrin is used in place of the iron porphyrin (porYCc) or fluorescent derivative of horse heart Cc with zinc substituted for iron in the heme (ZnHCc) in the presence of 25 µM dATP. PorYCc was excited at 515 nm, and emission was monitored at 620 nm. ZnHCc was excited at 550 nm, and emission was monitored at 587 nm (16).
Horse Cc Variants Generated in Escherichia coli-- The horse Cc mutants (from I to XXI in Table I) were also generated based on plasmid pBTR1 (18) by replacing the horse sequence with the corresponding sequence of yeast. An in vitro site-directed mutagenesis method is used to generate all the variants. All the mutants were cloned into XL-1 Blue strain (Stratagene) and confirmed by sequencing and then transformed into BL21 strain (DE3) (Stratagene) for protein overexpression.
Horse Cc Generated in Yeast-- Yeast strain B-8581 was used to generate the lysine 72 trimethylated horse Cc variant XXII. CNBr digestion and 1-D NMR experiments confirm the existence of the trimethyl group at position 72.
Yeast Cc Variants Generated in Yeast--
An in vivo
transformation method was used to mutate the yeast amino acids 1-9 and
53-60 (17). The parental yeast strain B-8163, which contains a
frameshift/stop codon at position 6 (TAAGT) was used to generate
mutant XXVI (S2D, A3V, K4E, A7K, T8K, L9I). Similarly, yeast
strain B-8162, which contains a frameshift/stop codon at position 52, is used to obtain mutant XXVII (I53K, K54N, N56G, V57I, L58T, D60K).
Yeast Cc Variants Generated in E. coli-- Plasmid pBTR1 (18) (a generous gift from Dr. Grant Mauk) was used to create nontrimethylated yeast Cc at position 72 (variant XXIII). The N-terminal codon was changed from ACT to GCT to create a restriction enzyme cutting site. This resulted in the mutation of amino acid 5 from Thr to Ala. A C102T mutation was introduced to diminish potential dimerization through disulfide bonds. Based on this plasmid, site-directed mutagenesis method is used to generate mutants XXIV and XXV.
Isolation of Recombinant Cytochrome c Mutants-- Cytochrome c variants expressed in E. coli were purified by a slightly modified procedure of Hampsey et al. (19) and Cutter et al. (20). Cell pellets from 2-liter culture were resuspended in lysis buffer (50 mM Tris, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, pH 7.5, 10 mM MgCl2, and 20 µg/ml DNase I). The lysate was treated with a French press (10,000 p.s.i.) and centrifuged at 40,000 × g for 30 min. The crude protein was cut at 55% (NH4)2SO4 (326 g/liter at 4 °C), and the supernatant was dialyzed against 12.5 mM potassium phosphate buffer, 1 mM EDTA, 2 mM 2-mercaptoethanol, pH 7.2. Ion-exchange purification (CM-Sepharose; Sigma) followed by a gel filtration (Superdex 30; Amersham Pharmacia Biotech) gave cytochrome c with a purity index A410/A280 of about 4.5. Homogeneity and purity of the variants were confirmed by electrospray mass spectrometry and SDS polyacrylamide gel electrophoresis. Conformationally sensitive bands in the variants are essentially conserved, suggesting that the Cc variants are folded properly, and the structures are intact. It should be noted that, unlike wild type horse Cc, the N-terminal glycine is not acetylated in horse Cc expressed in E. coli.
Procaspase-3 Assay of Caspase-9 Activation (2)--
2 µl of
Apaf-1 (100 ng) was incubated at 30 °C for 1 h with 1 mM dATP, 2 µl of purified procaspase-9 (12.5 ng),
in vitro-translated 35S-labeled procaspase-3,
and varying concentrations of cytochrome c variants. The
samples were subjected to 15% SDS polyacrylamide gel electrophoresis
and then transferred to a nitrocellulose filter, which was subsequently
exposed to a phosphorimaging plate and visualized in a Fuji BAS-1000 phosphorimager.
![]() |
RESULTS AND DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Fluorescence Polarization Data Show That Yeast Cytochrome c Binds
to Apaf-1 Much More Weakly than Does Horse Cytochrome
c--
ZnHCc and porYCc were used as fluorescent probes
because of their high structural homology to nonfluorescent iron
cytochrome c (21). When Apaf-1 (molecular mass = 130 kDa) was titrated into ZnHCc (molecular mass = 12 kDa) in the
presence of micromolar dATP, the fluorescence polarization increased
dramatically. Under the same experimental conditions, when Apaf-1 plus
a 20-fold excess of yeast Cc was titrated into a ZnHCc solution, a
similar trend of fluorescence polarization increase was observed (Fig.
2A). This implies that yeast
Cc does not compete with ZnHCc for binding Apaf-1. In a direct
titration experiment, no fluorescence polarization change was observed
when the fluorescent yeast protein porYCc was titrated with Apaf-1
(Fig. 2B). From these two sets of experiments, we conclude
that yeast Cc has relatively weak binding affinity for Apaf-1 compared
with horse Cc.
|
Site-directed Mutagenesis Results Indicate That a Large Part of the Cc Surface Residues Are Involved in Cc:Apaf-1 Recognition-- All the variants we examined are summarized in Table I. Here we found that when positions 7, 25, 39, 62-65, or 72 of the active horse sequence were mutated to the corresponding residues of inactive yeast Cc sequence, the induced caspase-9 activity in an in vitro reconstitution procaspase-3 cleavage assay was diminished. The effects of replacements seemed synergistic when the double and triple mutants were examined. By contrast, replacing residues 1-9 (XXVI) or 53-60 (XXVII) in the yeast background did not provide sufficient activity to be detected by our assay (data not shown).
|
When yeast sequence variations were introduced into horse Cc, several
mutated Cc showed significant effects on caspase-9 activation. Replacement of residues 7 and 8 (variant IV) resulted in a 10-fold decrease in the procaspase-3 cleavage assay when compared with wild
type horse Cc (Fig. 3A,
lane 3). The variant VII (K39H) produced an ~5-fold
decrease in activity. The variant VIII (K25P/K39H) generated a more
than 10-fold drop in activity (data not shown). Replacement of residues
62-65 (variant XVI) decreased the activity about 10-fold with the
major effect contributed by 62 (variant IX; Fig. 3A,
lane 4). This effect is amplified by introducing multiple
mutations. For example, the variants XI (K7E/K8E/E62N/K39H) (Fig.
3B, lane 6) and XVIII
(K7E/K8E/E62N/T63N/L64M/M65S/K25P) (Fig. 3A, lane
5) showed more than 1000-fold decrease in the caspase activation
activity.
|
Interestingly, horse Cc, when expressed and purified from yeast, is trimethylated at position 72. This variant, XXII (K72X), had little caspase-9 activating activity (Fig. 3B, lane 8). Similar results have been reported previously (24). The importance of this position was further underscored by the variant XXI (K72A), which showed no detectable caspase-9 activating activity at all (Fig. 3B, lane 7). We also generated yeast Cc from E. coli. The Lys-72 of recombinant yeast Cc generated this way is not trimethylated (18). This variant, XXIII, showed significant caspase-9 activation activity, even though the activity was well below the wild type horse Cc (Fig. 3C, lane 2).
When the XXIII variant was further modified from the yeast sequence to
the horse sequence at the positions 7, 25, 39, and 62-65 (variant
XXIV), the caspase-9 activation was enhanced to a level similar to the
wild type horse Cc (Fig. 3C, lane 3). The activity of the variant XXIV was further enhanced when the N-terminal sequence (5 to
1) found in fungi was eliminated. The resulting variant XXV showed apoptotic activity that was equal to or that even
exceeded that of wild type horse Cc (Fig. 3C, lane
4).
In summary, these results showed that when residues 7, 25, 39, and 62-65 of yeast were substituted with the corresponding horse Cc amino acids, caspase-9 activation was dramatically increased. On the other hand, when these same amino acids in horse Cc were replaced by the corresponding yeast Cc sequence, a more than 1000-fold drop in caspase-9 activation was observed. Taken together, these results indicate that 7, 25, 39, and 62-65 are critical amino acids for Cc:Apaf-1 interaction.
Because positions 7, 25, 39, 62-65, and 72 are so widely dispersed on
the surface of Cc (Fig. 4), we conclude
that Cc:Apaf-1 recognition involves a large region of the Cc surface.
It seems that Cc is almost fully "wrapped" by Apaf-1, which is
consistent with the high binding constant of Cc and Apaf-1 (8). The
hypothetical binding model for Cc binding to Apaf-1 includes the Apaf-1
WD-40 domain (22, 23), a beta-sheet barrel that could encompass much of
the Cc surface. Although the binding surface is extensive, the amino
acids on the binding interface do not seem to contribute equally. In
this work, we have pinpointed several central amino acids that
substantially affect the apoptotic activity of Cc when mutated.
In contrast, mutations at other amino acids did not affect its
apoptotic activity. For example, replacement of lysine 7 had a much
reduced apoptotic activity than the replacement of lysine 8, and
replacement of valine 11 had no effect at all (data not shown).
|
The contribution of individual residues is almost additive. The variants V (K7E/K8E), IX (E62N), and VIII (K25P/K39H) individually showed an ~10-fold reduction in caspase-9-activating activity. When variant V and variant IX were combined to make the variant X (Fig. 3B, lane 2), a 100-fold drop in activity was observed. The variant XII, which combines all three mutations, exhibited a greater than 1000-fold drop in caspase-9 activation (Fig. 3A, lane 7). The similar synergistic trend was seen with the variants XVI (E62N/T63N/L64M/M65S) (data not shown), XVII (data not shown), XVIII, XIX, and XX (Fig. 3A, lanes 5, 6, and 8), variants VI (K7A) (data not shown), XIII, XIV, and XV (Fig. 3B, lanes 3, 4, and 5).
Conclusions--
The binding interface inferred for Cc:Apaf-1
binding is unusual. All previous (electron transfer) partners of Cc
bind at the "front face" of Cc, with the lysine-rich interface in
close proximity to the heme (6). In contrast, in Apaf-1 binding, Cc
uses not only this front face, but also an opposite surface
centered around positions 39 and 62-65. This large interface explains
both the unusually high binding affinity between Cc and Apaf-1 (16) and the ionic strength dependence of the binding (25). The binding region
identified here also explains the striking differences in activity
between the highly homologous horse Cc and yeast Cc (13). Interactions
from both the 62-65 region and specific front face lysine
(e.g. 7, 25, and 72) contribute to overall
binding and activity. Because the contributions from each subset appear to be essentially independent, a single subset might be targeted to
affect overall binding. We are investigating a possibility to use small
molecules to affect the binding of Cc to Apaf-1. Initial results
suggest that designed synthetic molecules can indeed compete with the
Cc:Apaf-1 binding interaction.
![]() |
ACKNOWLEDGEMENTS |
---|
T. Y. thanks Yudong Wu, Drs. Stacy S. Springs, Martin A. Case, Rachael A. Kipp, and Federico Rosell for helpful discussions and critical reading of manuscript, and Dr. Chunying Du for providing the reagents and making the figures.
![]() |
FOOTNOTES |
---|
* This work is supported in part by National Institutes of Health Grants GM59348 (to G. M.) and GM57158 and Welch Foundation Grant I1412 (to X. W.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Dept. of Chemistry, Princeton University, Princeton, NJ 08544. Tel.: 609-258-3916; Fax: 609-258-6746; E-mail: glm@princeton.edu (for G. L. M.) and HHMI & Dept. of Biochemistry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235-9038. Tel.: 214-648-6713; Fax: 214-648-5419; E-mail: xwang@biochem.swmed.edu (for X. W.).
Published, JBC Papers in Press, December 8, 2000, DOI 10.1074/jbc.M009773200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are: Cc, cytochrome c, Apaf-1, apoptosis protease activation factor-1; porYCc, porphyrin yeast cytochrome c; ZnHCc, zinc derivative of horse cytochrome c.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. (1997) Cell 91, 479-489[Medline] [Order article via Infotrieve] |
2. | Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. (1997) Cell 90, 405-413[Medline] [Order article via Infotrieve] |
3. | Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S. (1998) Mol. Cell 1, 949-957[Medline] [Order article via Infotrieve] |
4. |
Hu, Y.,
Benedict, M. A.,
Ding, L.,
and Nunez, G.
(1999)
EMBO J.
18,
3586-3595 |
5. |
Zou, H.,
Li, Y.,
Liu, X.,
and Wang, X.
(1999)
J. Biol. Chem.
274,
11549-11556 |
6. |
Cain, K.,
Brown, D. G.,
Langlais, C.,
and Cohen, G. M.
(1999)
J. Biol. Chem.
274,
22686-22692 |
7. | Pan, G., Humke, E. W., and Dixit, V. M. (1998) FEBS Lett. 426, 151-154[CrossRef][Medline] [Order article via Infotrieve] |
8. |
Slee, E. A.,
Harte, M. T.,
Kluck, R. M.,
Wolf, B. B.,
Casiano, C. A.,
Newmeyer, D. D.,
Wang, H. G.,
Reed, J. C.,
Nicholson, D. W.,
Alnemri, E. S.,
Green, D. R.,
and Martin, S. J.
(1999)
J. Cell Biol.
144,
281-292 |
9. | Skulachev, V. P. (1998) FEBS Lett. 423, 275-280[CrossRef][Medline] [Order article via Infotrieve] |
10. | Mignotte, B., and Vayssiere, J. L. (1998) Eur. J. Biochem. 252, 1-15[Abstract] |
11. | Bossy-Wetzel, E., and Green, D. R. (1999) Mutat. Res. 434, 243-251[Medline] [Order article via Infotrieve] |
12. | Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. (1999) Annu. Rev. Cell Dev. Biol. 15, 269-290[CrossRef][Medline] [Order article via Infotrieve] |
13. |
Kluck, R. M.,
Martin, S. J.,
Hoffman, B. M.,
Zhou, J. S.,
Green, D. R.,
and Newmeyer, D. D.
(1997)
EMBO J.
16,
4639-4649 |
14. |
Rieder, R.,
and Bosshard, H. R.
(1980)
J. Biol. Chem.
255,
4732-4739 |
15. | Kang, C. H., Ferguson-Miller, S., and Margoliash, E. (1977) J. Biol. Chem. 252, 919-926[Abstract] |
16. | Purring, C., Zou, H., Wang, X. D., and McLendon, G. (1999) J. Am. Chem. Soc. 121, 7435-7436[CrossRef] |
17. | Moerschell, R. P., Das, G., and Sherman, F. (1991) Methods Enzymol. 194, 362-369[Medline] [Order article via Infotrieve] |
18. | Pollock, W. B., Rosell, F. I., Twitchett, M. B., Dumont, M. E., and Mauk, A. G. (1998) Biochemistry 37, 6124-6131[CrossRef][Medline] [Order article via Infotrieve] |
19. |
Hampsey, D. M.,
Das, G.,
and Sherman, F.
(1986)
J. Biol. Chem.
261,
3259-3271 |
20. | Cutler, R. L., Pielak, G. J., Mauk, A. G., and Smith, M. (1987) Protein Eng. 1, 95-99[Abstract] |
21. | Anni, H., Vanderkooi, J. M., and Mayne, L. (1995) Biochemistry 34, 5744-5753[Medline] [Order article via Infotrieve] |
22. |
Hu, Y.,
Ding, L.,
Spencer, D. M.,
and Nunez, G.
(1998)
J. Biol. Chem.
273,
33489-33494 |
23. |
Adrain, C.,
Slee, E. A.,
Harte, M. T.,
and Martin, S. J.
(1999)
J. Biol. Chem.
274,
20855-20860 |
24. |
Kluck, R. M.,
Ellerby, L. M.,
Ellerby, H. M.,
Naiem, S.,
Yaffe, M. P.,
Margoliash, E.,
Bredesen, D.,
Mauk, A. G.,
Sherman, F.,
and Newmeyer, D. D.
(2000)
J. Biol. Chem.
275,
16127-16133 |
25. |
Purring-Koch, C.,
and McLendon, G.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
11928-11931 |
26. | Voet, D., and Voet, J. G. (1995) Biochemistry , 2nd Ed. , pp. 126-127, Wiley, New York |
27. | Merritt, E. A., and Murphy, M. E. P. (1994) Acta Crystallogr. Section D-Biological Crystallography 50, 869-873 |
28. | Kraulis, P. J. (1991) J. Appl. Crystallogr. 24, 946-950[CrossRef] |